Subscribe To
CRL / Charles River (CRL) Benefits From Price Rise Amid FX Woe
CRL News
By Market Watch
November 2, 2023
Consulting firm Charles River raises dividend to boost yield above the S&P 500's, while profit and revenue miss expectations
CRA International Inc. CRAI, +0.09%, the consulting firm also known as Charles River Associates, said Thursday that it raised its quarterly dividend, more_horizontal
By Zacks Investment Research
November 1, 2023
Charles River (CRL) to Report Q3 Earnings: What's in Store?
Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the more_horizontal
By Zacks Investment Research
October 24, 2023
Why Charles River (CRL) Could Beat Earnings Estimates Again
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely more_horizontal
By Zacks Investment Research
October 10, 2023
Here's Why You Should Retain Charles River (CRL) Stock Now
Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance. more_horizontal
By InvestorPlace
October 5, 2023
Q4 Stock Predictions: 3 S&P 500 Stocks Ready to Soar
Stocks ended the third quarter on a sour note. The Federal Reserve's aggressive posture against inflation combined with soaring interest rates have in more_horizontal
By Zacks Investment Research
October 2, 2023
Charles River (CRL) Launches LVV-based Gene Therapy Platform
Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market. more_horizontal
By Zacks Investment Research
September 26, 2023
Charles River (CRL) Opens a RightSource Lab in Stevenage
Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster. more_horizontal
By Zacks Investment Research
September 15, 2023
Charles River (CRL) Announces Partnership With Related Sciences
Charles River's (CRL) new collaboration is likely to leverage the AI-powered drug discovery and development platform, Logica. more_horizontal